2,5 million people across the world live with systemic sclerosis

Systemic sclerosis is a chronic inflammatory disease characterized by severe clinical symptoms which restrict normal daily activities. Gesynta Pharma develops innovative pharmaceuticals with the aim to treat systemic sclerosis and other complex medical conditions.

READ MORE

Our drug candidates

Gesynta Pharma’s drug candidates utilize a unique mechanism of action to reduce inflammation and pain, and increase healthy blood flow. We are currently developing three drug candidates. One of the compounds has reached clinical phase IIa stage. A second one will start clinical testings in 2022. Read more about our drug development projects.

Therapeutic areas

Understanding microvascular dysfunction

READ MORE

Development pipeline

GS-248 - our most advanced drug candidate

READ MORE

About us

A well-composed team with vast experience

READ MORE

Development pipeline

Unique treatments of chronic inflammation

READ MORE

Development pipeline

Our current activities

Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby aiming to provide improved treatments for several serious diseases. In an ongoing clinical  phase IIa study, GS-248 is being evaluated for its potential to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular and rheumatic diseases.

READ MORE

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.

Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.

Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.

Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.